CoChat

Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial

Tanaka, Atsushi, Shimabukuro, Michio, Machii, Noritaka, Teragawa, Hiroki, Okada, Yosuke, Shima, Kosuke R., Takamura, Toshinari, Taguchi, Isao, Hisauchi, Itaru, Toyoda, Shigeru, Matsuzawa, Yasushi, Tomiyama, Hirofumi, Yamaoka-Tojo, Minako, Yoshida, Hisako, Sato, Yasunori, Ikehara, Yumi, Ueda, Shinichiro, Higashi, Yukihito, Node, Koichi, EMBLEM Investigators, Ako, Junya, Amano, Hirohisa, Inoue, Teruo, Jinnouchi, Hideaki, Kawaguchi, Atsushi, Kawano, Yoshiyuki, Kimura, Kazuo, Kurozumi, Akira, Kusumoto, Takaaki, Maruhashi, Tatsuya, Misu, Hirofumi, Nakamura, Katsunori, Narisawa, Manabu, Nishi, Junya, Ota, Tsuguhito, Oyama, Jun-ichi, Sakuma, Masashi, Shiina, Kazuki, Sugiyama, Seigo, Suzuki, Kunihiro, Takahashi, Naohiko, Takemoto, Yasuhiko, Takeshita, Yumie, Tamaki, Hiroshi, Tamura, Akira, Tanaka, Kenichi, Toita, Takafumi, Torimoto, Keiichi, Uehara, Hiroki, Uemura, Fumi, Yamakawa, Ken, Yufu, Kunio · 2019 · Diabetes Care
Cited by 60

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Recent large trials on sodium–glucose cotransporter 2 (SGLT2) inhibitors showed that these agents improved cardiovascular outcomes in patients with type 2 diabetes (T2D) with a high risk of cardiovascular events (1). However, the underlying mechanisms of these clinical benefits and vascular effect of SGLT2 inhibitors in that patient group remain uncertain. Endothelial dysfunction is exacerbated by metabolic disorders, such as diabetes, and involved in the pathophysiology of diabetes-related cardiovascular complications (2,3). We therefore investigated whether empagliflozin added to standard therapy, compared with placebo, affected endothelial function in patients with T2D and established cardiovascular disease (CVD). This was a prospective, multicenter, randomized, placebo-controlled, double-blind clinical trial undertaken in 16 centers in Japan (clinical trial reg. no. UMI24502, www.umin.ac.jp/ctr/index.htm) (4). A total of 117 adults with T2D and established CVD were randomized (1:1) to receive either empagliflozin 10 mg daily or placebo for 24 weeks. Randomization was performed by using the web-based minimization dynamic allocation method stratified according to HbA1c, age, systolic blood pressure (BP), and smoking status. The placebo was indistinguishable from empagliflozin, and both study drugs were sequentially numbered and concealed. The participants and investigators remained masked to group assignments until the database lock (an action taken to prevent further changes to a clinical trial database). The effects of treatment on endothelial function were assessed by the reactive hyperemia peripheral arterial tonometry index (RHI) (5), with the primary efficacy end point being the change in RHI from baseline to 24 weeks. Ethics approval and informed patient consent were obtained. Of the 117 patients, 105 were included in the full analysis set. Ten patients dropped out prior to initiation of the study drug, and two patients in the placebo group were excluded due to a serious protocol deviation (lack of data …

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc19-1177

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 4

  1. Paneni, 2013, Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I, Eur Heart J, 34, 2436, 10.1093/eurheartj/eht149 · DOI · Paper page
  2. Xu, 2009, Molecular insights and therapeutic targets for diabetic endothelial dysfunction, Circulation, 120, 1266, 10.1161/CIRCULATIONAHA.108.835223 · DOI · Paper page
  3. Tanaka, 2017, Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial, Cardiovasc Diabetol, 16, 48, 10.1186/s12933-017-0532-8 · DOI
  4. Kuvin, 2003, Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude, Am Heart J, 146, 168, 10.1016/S0002-8703(03)00094-2 · DOI · Paper page

Cited by

See all 60

Metadata

Authors
Tanaka, A., Shimabukuro, M., Machii, N., Teragawa, H., Okada, Y., Shima, K. R., Takamura, T., Taguchi, I., Hisauchi, I., Toyoda, S., Matsuzawa, Y., Tomiyama, H., Yamaoka-Tojo, M., Yoshida, H., Sato, Y., Ikehara, Y., Ueda, S., Higashi, Y., Node, K., EMBLEM Investigators, Ako, J., Amano, H., Inoue, T., Jinnouchi, H., Kawaguchi, A., Kawano, Y., Kimura, K., Kurozumi, A., Kusumoto, T., Maruhashi, T., Misu, H., Nakamura, K., Narisawa, M., Nishi, J., Ota, T., Oyama, J.-I., Sakuma, M., Shiina, K., Sugiyama, S., Suzuki, K., Takahashi, N., Takemoto, Y., Takeshita, Y., Tamaki, H., Tamura, A., Tanaka, K., Toita, T., Torimoto, K., Uehara, H., Uemura, F., Yamakawa, K., & Yufu, K.
Venue
Diabetes Care
Published
2019-09-12
Volume
42
Issue
10
Pages
e159-e161
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2974835615
Cited by
60
References
1
FWCI
6.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial. https://app.cochat.ai/papers/10.2337/dc19-1177
The paper
Tanaka, A., Shimabukuro, M., Machii, N., Teragawa, H., Okada, Y., Shima, K. R., Takamura, T., Taguchi, I., Hisauchi, I., Toyoda, S., Matsuzawa, Y., Tomiyama, H., Yamaoka-Tojo, M., Yoshida, H., Sato, Y., Ikehara, Y., Ueda, S., Higashi, Y., Node, K., . . . Yufu, K. (2019). Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial. Diabetes Care. https://doi.org/10.2337/dc19-1177

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.